电可以减少粉样β的积累,并以依赖N6-甲基亚登素的方式改善脑缺血引起的认知障碍
Jianbo Yang1, Jinfeng Xu2, Xiaoyang Wang3
1Department of Neurology, The Fourth Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, China.
Journal of molecular histology
|January 12, 2026
概括
电疗法通过向METTL3/BACE1通路来改善脑缺血后的认知功能. 这种治疗减少了粉样β积累和神经元损失,为中风恢复提供了潜在的机制.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 脑缺血 (CI) 后的认知障碍是一个重大的临床挑战.
- 电针 (EA) 是中国广泛使用的CI治疗方法,但其分子机制尚不清楚.
- 粉样β (Aβ) 积累和神经元损失是CI的关键病理特征.
研究的目的:
- 阐明EA在治疗脑缺血 (CI) 后认知障碍中的分子机制.
- 调查METTL3/BACE1轴和N6-甲基氨酸 (m6A) 修饰在EA治疗效果中的作用.
主要方法:
- 为CI建立了一个永久的中脑动脉封闭 (pMCAO) 鼠标模型.
- 使用莫里斯水迷宫 (MWM) 测试评估认知功能.
- 通过Nissl染色量化神经元生存率和使用ELISA测量Aβ水平.
- 在HT22细胞中利用氧-葡萄糖剥夺 (OGD) 进行体外机理学研究.
- 在海马组织中评估了METTL3表达和m6A水平.
主要成果:
- 在pMCAO小鼠中,EA治疗显著改善了学习和记忆.
- EA治疗抑制了海马神经元损失,并降低了Aβ40和Aβ42水平.
- 在pMCAO小鼠中升高的METTL3和m6A水平被EA降低.
- 在体外,METTL3通过其mRNA上的m6A丰富对BACE1进行了上调调节,增加了Aβ的产生和亡.
- 在pMCAO小鼠中,EA治疗抑制了METTL3/BACE1轴,缓解了Aβ积累和认知缺陷.
结论:
- 在CI的小鼠模型中,EA治疗有效地改善了认知功能障碍.
- 该研究确定了由m6A调节的METTL3/BACE1轴,作为EA的一个关键分子标.
- 这些发现揭示了EA在治疗脑性缺血后认知障碍的新治疗机制.
更多相关视频
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
44.1K
05:54Author Spotlight: Exploring Acupuncture in Alzheimer's Research from Thread-Embedding Techniques to Clinical Trials
Published on: May 10, 2024
2.0K
相关概念视频
Alzheimer's Disease: Treatment
801
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
801
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
535
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
535
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
